News
SECOND DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO’S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Bergen, Norway, 8th February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO PRESENTS UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory…
Read MoreBERGENBIO ASA: INVITATION TO FOURTH QUARTER 2020 RESULTS
Bergen, Norway, 27 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO TO PRESENT UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory…
Read MoreBERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES
Bergen, Norway, 12 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreDATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO’S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Bergen, Norway, 11 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
